No Photo Available

Last Update

2017-01-30T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Bruce Weintraub?

Dr. Bruce D. Weintraub

President, Chief Executive Officer and Cofounder

Trophogen Inc

Direct Phone: (301) ***-****       

Email: b***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Trophogen Inc

9714 Medical Center Drive Suite 1114

Rockville, Maryland 20850

United States

Company Description

Trophogen, Inc. is a U.S.-based biotechnology company founded in 2001 with Series A funding from Toucan Capital, focusing on the development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs for human in ... more

Find other employees at this company (5)

Background Information

Employment History

Director of the Endocrinology Training Program

National Institutes of Health

Assistant Professor

Harvard University

Affiliations

Fellow
Keck Joint Science Department

Education

BA

MDfrom Harvard University

BA

Princeton University

MD

Web References (25 Total References)


Organization: Trophogen Inc. Improving Human and Animal Health With Protein Engineering.

www.trophogen.com [cached]

Bruce D. Weintraub, MD President, CEO & Co-Founder

Dr. Weintraub has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors. He is the author of over 300 scientific papers, reviews and book chapters. In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors. He is well known for his basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion. In addition he was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors. He is particularly recognized for his role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.
Dr. Weintraub obtained his BA from Princeton University magna cum laude where he was elected to Phi Beta Kappa and his MD from Harvard University cum laude where he was elected to Alpha Omega Alpha. His postdoctoral clinical and basic science training were at Harvard and the National Insitutes of Health and he later served as Assistant Professor at Harvard. In 1972 he became the first Director of the NIH Endocrinology Training Program and later Chief of its Molecular and Cellular Endocrinology Branch, positions he held until 1995. In both these positions he helped train a generation of leading international academic and clinical endocrinologists. From 1996- 2001 he was Professor of Medicine at the University of Maryland at Baltimore, Chief of the Laboratory of Molecular Endocrinology of the Institute of Human Virology of the University of Maryland Biotechnology Institute and Director of the Thyroid Cancer Program of the Greenebaum Cancer Center. He has received numerous international awards and lectureships, is a member of many scientific research organizations, served on several journal editorial boards as well as on several advisory committees to NIH and various universities. He has also served on the Council of the Endocrine Society and the American Thyroid Association as well as President of the Maryland Endocrine Society.


Bruce ...

www.mentorhealth.com [cached]

Bruce Weintraub President and CEO, Trophogen

Dr. Weintraub has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors. He is the author of over 300 scientific papers, reviews and book chapters. In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors.
He is well known for his basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion. In addition he was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors. He is particularly recognized for his role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.


Trophogen :: About :: Organization

www.trophogen.com [cached]

Bruce D. Weintraub, MD President & CEO

Dr. Weintraub has more than 30 years experience in a biomedical research career that has focused on molecular, cellular, clinical and therapeutic aspects of glycoprotein hormones, related growth factors, thyroid hormone and their receptors. He is the author of over 300 scientific papers, reviews and book chapters. In addition has several issued and pending patents related to the cloning of the human TSH beta subunit, development of recombinant TSH, and development of superactive analogs of TSH, gonadotropins and related cystine knot growth factors. He is well known for his basic science work related to pituitary and recombinant TSH synthesis, glycosylation and action, affinity chromatography as well as clinical aspects of syndromes of inappropriate TSH secretion. In addition he was among the first to recognize and define the clinical and molecular aspects of thyroid hormone resistance, TSH- producing pituitary tumors and ectopic production of placental hormones and free subunits by various tumors. He is particularly recognized for his role as coinventor, codeveloper and a leading investigator in the international clinical trials of recombinant TSH, approved by the FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized the approach world -wide to that disease.
Dr. Weintraub obtained his BA from Princeton University magna cum laude where he was elected to Phi Beta Kappa and his MD from Harvard University cum laude where he was elected to Alpha Omega Alpha. His postdoctoral clinical and basic science training were at Harvard and the National Insitutes of Health and he later served as Assistant Professor at Harvard. In 1972 he became the first Director of the NIH Endocrinology Training Program and later Chief of its Molecular and Cellular Endocrinology Branch, positions he held until 1995. In both these positions he helped train a generation of leading international academic and clinical endocrinologists. From 1996- 2001 he was Professor of Medicine at the University of Maryland at Baltimore, Chief of the Laboratory of Molecular Endocrinology of the Institute of Human Virology of the University of Maryland Biotechnology Institute and Director of the Thyroid Cancer Program of the Greenebaum Cancer Center. He has received numerous international awards and lectureships, is a member of many scientific research organizations, served on several journal editorial boards as well as on several advisory committees to NIH and various universities. He has also served on the Council of the Endocrine Society and the American Thyroid Association as well as President of the Maryland Endocrine Society.
...
She then joined Dr. Weintraub and Dr. Szkudlinski at the Institute of Human Virology, University of Maryland, Baltimore and contributed to the elucidation of the mechanism of activation of the TSH receptor.


Advanced Bioscience Laboratories

www.ablinc.com [cached]

"Trophogen is very pleased that the lead product of its large portfolio of more potent/efficacious and longer acting human and bovine recombinant superagonist analogs will be commercialized with ABL's expert assistance," said Dr. Bruce Weintraub, President and COO of Trophogen.


Bioniche

www.bioniche.com [cached]

Dr. Bruce Weintraub, President of Trophogen commented, "It is very gratifying for Trophogen to partner with Bioniche, a world renowned leader in veterinary reproduction, to develop its recombinant superagonist technology for this market."

Similar Profiles

Other People with this Name

Other people with the name Weintraub

Peter Weintraub
FIDF

Lori Weintraub
Desert De Oro Foods Inc

Rebecca Weintraub
Granite Telecommunications LLC

Joshua Weintraub
Cerberus Capital Management LP

Danielle Weintraub
AFV Inc.

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory